Affitope AD01

Drug Profile

Affitope AD01

Alternative Names: AD 01 - AFFiRiS; AD-1; Alzheimer AD01

Latest Information Update: 25 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AFFiRiS
  • Class Alzheimer vaccines; Antidementias
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Alzheimer's disease

Most Recent Events

  • 19 Nov 2009 Suspended - Phase-I for Alzheimer's disease in Austria (SC)
  • 20 Oct 2009 A phase I trial met its primary endpoint of safety and tolerability in patients with Alzheimer's disease
  • 16 Sep 2009 Interim adverse events data from phase I trials in Alzheimer's disease presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top